 TORONTO, Nov. 30, 2020 GLOBE NEWSWIRE -- Profound Medical Corp. NASDAQ:PROF; TSX:PRN Profound or the Company announced today that Sonalleve has received U.S. Food and Drug Administration FDA approval under a Humanitarian Device Exemption HDE for the treatment of osteoid osteoma. 